glp 1 analogue moa Recent updates on GLP-1 agonists: Current advancements & challenges Discovery of GLP-1–Based Drugs for

The study cohort included more than 132,500 and 201,100 incident users of GLP-1s and sulfonylureas, respectively

doi: 10.3389/fnut.2025.1702028 Received 09 September 2025 Revised 09 December 2025 Accepted 10 December 2025 Published 08 January 2026 Volume 12 - 2025 Edited by Lus Pedro Rato, University of vora, Portugal Reviewed by Jean-Marie Exbrayat, Catholic University of Lyon, France Ayad Palani, University of Garmian, Iraq Kosar Babaei, Neyshabur University of Medical Sciences, Iran Updates Copyright 2026 Zeevi, arac, Perovi, Zekovi and Stojsavljevi

Given that GLP-1 is secreted postprandially and GLP-1-mediated incretin effect contributes to the glucose-lowering effect of T3, we decided to compare the T3-reuglated pathways with those pathways altered in response to oral intake of nutrients

1998 Jun;9(6):1060-6 Lu SC